According to our (Global Info Research) latest study, the global Cell Banking Outsourcing market size was valued at US$ 11130 million in 2025 and is forecast to a readjusted size of US$ 30600 million by 2032 with a CAGR of 15.7% during review period.
Cell Banking Outsourcing refers to the practice of delegating the critical processes of collecting, processing, expanding, and storing cell samples—such as stem cells, immune cells, or genetically engineered cells—to specialized third-party service providers. This service involves standardized GMP-compliant biobanking procedures, stringent quality control, and full lifecycle data traceability. With the rapid expansion of precision medicine, cell therapies, and biopharmaceutical R&D, outsourced cell banking is becoming a vital infrastructure across the global healthcare and life sciences industries, bridging the gap from clinical research to commercial application.
The global biopharmaceutical sector is undergoing structural transformation, with emerging therapies such as cell and gene therapy driving a surge in demand for large-scale, high-quality cell sample banking. Biotech companies are increasingly favoring asset-light R&D models, outsourcing cell banking, QC, and storage to specialized providers with GMP or ISO certifications to enhance efficiency and reduce operational burden. Meanwhile, national policies in countries like China, the U.S., South Korea, and Singapore continue to prioritize cell banking as a strategic infrastructure initiative. These factors jointly propel the Cell Banking Outsourcing market into a high-growth trajectory, attracting both capital and industry attention as a critical enabling service. Despite strong demand, the sector faces considerable hurdles. Global disparities in regulation—especially in areas such as sample cross-border transfer, ethical approvals, and data sovereignty—present compliance complexities. The industry has high entry barriers, requiring significant investment in infrastructure, certified personnel, and quality systems. Client expectations around data integrity, biosafety, and long-term storage reliability are also rising, leading to market consolidation. As a result, while leading providers strengthen their positions, smaller players face increasing operational and competitive pressures.Demand is shifting from early-stage academic and research applications to late-phase and commercial clinical programs, especially in CAR-T, iPSC-based regenerative therapies, and personalized immunotherapies. Phase III+ trials require stricter sample handling and storage protocols. Additionally, global pharma and CRO/CMO players are reshaping their supply chains, driving the adoption of multi-site collection, regionalized biobanking, and real-time digital traceability systems. The future will favor providers offering integrated, automated, and fully compliant services—emerging as platform-centric and ecosystem-leading companies in a rapidly maturing landscape.
This report is a detailed and comprehensive analysis for global Cell Banking Outsourcing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cell Banking Outsourcing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Cell Banking Outsourcing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Cell Banking Outsourcing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Cell Banking Outsourcing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cell Banking Outsourcing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cell Banking Outsourcing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include SGS Life Sciences, Lonza, CCBC, Vcanbio, AMAG Pharmaceuticals, ViaCord, Thermo Fisher, Wuxi Apptec, CordLife, Esperite, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Cell Banking Outsourcing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Stem Cell Banking
Non-stem Cell Banking
Market segment by Application
Cell Bank Storage
Bank Characterization and Testing
Cell Bank Preparation
Market segment by players, this report covers
SGS Life Sciences
Lonza
CCBC
Vcanbio
AMAG Pharmaceuticals
ViaCord
Thermo Fisher
Wuxi Apptec
CordLife
Esperite
Reliance Life Sciences
Lifecell
Cryo-Cell
Toxikon
Goodwin Biotechnology
Texcell
Cryo Stemcell
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cell Banking Outsourcing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cell Banking Outsourcing, with revenue, gross margin, and global market share of Cell Banking Outsourcing from 2021 to 2026.
Chapter 3, the Cell Banking Outsourcing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Cell Banking Outsourcing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cell Banking Outsourcing.
Chapter 13, to describe Cell Banking Outsourcing research findings and conclusion.
Summary:
Get latest Market Research Reports on Cell Banking Outsourcing. Industry analysis & Market Report on Cell Banking Outsourcing is a syndicated market report, published as Global Cell Banking Outsourcing Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Cell Banking Outsourcing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.